Knight Therapeutics SMA 200
Cos'è SMA 200 di Knight Therapeutics?
SMA 200 di Knight Therapeutics, Inc. è CAD$6 +5.48%
Qual è la definizione di SMA 200?
SMA 200 è un prezzo medio delle azioni degli ultimi 200 giorni calcolato come media non ponderata dei precedenti 200 prezzi di chiusura delle scorte.
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 200 di aziende nel Health Care settore su TSX rispetto a Knight Therapeutics
Cosa fa Knight Therapeutics?
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer. The company also provides Burinex, for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome; PROBUPHINE, to treat opioid addiction; and MOVANTIK for the treatment of opioid-induced constipation. In addition, it offers Vidaza to treat myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven to treat advanced or metastatic breast cancer; Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma; Ladevina to treat multiple myeloma; Zyvalix for metastatic prostate cancer; Karfib to treat relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; AmBisome and Cresemba to treat fungal infection; and Impavido for leishmaniasis. Further, the company provides Ursofalk to treat biliary cirrhosis; Salofalk for ulcerative colitis; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Aziende con sma 200 simili a Knight Therapeutics
- Propel Funeral Partners ha SMA 200 di AUD$6 +4.69%
- Passat SA ha SMA 200 di €6 -20.28%
- China Railway Signal & Communication ha SMA 200 di ¥6 -15.91%
- Zambeef Products Plc ha SMA 200 di GBX6 +1.61%
- Serve Robotics Inc ha SMA 200 di $6 +18.35%
- Leverage Sha Etp 2070 ha SMA 200 di €6 +6.83%
- Knight Therapeutics ha SMA 200 di CAD$6 +5.48%
- Harbour Centre Development ha SMA 200 di HKD$6 -14.50%
- Meridian ha SMA 200 di AUD$6 +0.01%
- QIWI plc ha SMA 200 di $6 +0.00%
- Value8 NV ha SMA 200 di €6 -1.28%
- Far East Horizon ha SMA 200 di HKD$6 -6.02%
- Trilogiq SA ha SMA 200 di €6 +3.86%